Skip to main content

Table 2 Detection of ANA and anti-dsDNA autoantibodies during infliximab treatment

From: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

  Number of positive sera ANA Anti-dsDNA autoantibodies
Infliximab RA (n = 24) n 0 9 1
  n i12 12 10
  n i24 13 13
  n t 22 14
Infliximab AS (n = 15) n 0 2 2
  n i12 8 3
  n i24 11 4
  n t 13 6
Control RA (n = 30) n 0 5 0
  n i12 4 2
  n t 9 2
  1. ANA, antinuclear autoantibodies; anti-dsDNA, anti-double-stranded DNA autoantibodies; n0, number of positive sera before treatment; ni12, number of positive sera-induced autoantibodies after 12 months of treatment; ni24, number of positive sera-induced autoantibodies after 24 months of treatment; nt, number of positive sera before treatment plus number of induced autoantibodies during infliximab treatment.